China is one of the few countries with operational heavy-ion therapy alongside proton therapy. Here is how the three modalities differ, where each fits clinically, and what they cost.
China has multiple operational proton centres and is one of a small number of countries with operational heavy-ion (carbon ion) facilities. Leading centres:
The Three Modalities
- Photon (X-ray) therapy — IMRT, VMAT, SBRT — the standard radiotherapy at every Class A oncology centre globally; latest technology gives high conformity
- Proton therapy — uses charged proton beams with a Bragg peak, allowing dose to be deposited primarily at depth with minimal exit dose; reduces normal-tissue exposure
- Heavy-ion therapy — typically carbon ions; higher relative biological effectiveness (RBE) than photons or protons, particularly useful for radioresistant tumours
Where China Sits Globally
China has multiple operational proton centres and is one of a small number of countries with operational heavy-ion (carbon ion) facilities. Leading centres:
- Shanghai Proton and Heavy Ion Hospital (SPHIC): dual proton and carbon ion facility; one of the largest in Asia
- Wuwei Heavy Ion Center (Gansu): heavy-ion facility, one of few worldwide
- Multiple proton-only centres across major academic medical centres
When Each Modality Is Appropriate
Most patients are best served by modern photon-based IMRT/VMAT/SBRT, which delivers excellent outcomes for the majority of tumour types. Proton therapy adds value where reducing normal-tissue dose is critical — paediatric tumours, tumours adjacent to critical organs (skull base, spinal cord, mediastinum), and re-irradiation cases. Heavy-ion therapy is preferred for selected radioresistant tumours (some sarcomas, recurrent rectal cancers, certain head-and-neck cancers, and selected hepatocellular carcinomas).
Indication Examples
- Paediatric brain and CNS tumours: proton therapy commonly preferred to spare developing tissue
- Hepatocellular carcinoma: proton or carbon-ion stereotactic ablative therapy is increasingly used for selected non-resectable cases
- Skull base and head-and-neck: proton or heavy-ion benefits for chordomas, chondrosarcomas, recurrent disease
- Prostate cancer: evidence is mixed; modern photon SBRT delivers comparable outcomes for most patients
- Lung cancer (early-stage non-resectable): SBRT photon is standard-of-care; proton in selected centrally-located tumours
- Recurrent or radioresistant sarcomas: heavy-ion is among the strongest indications
Cost Comparison
- Photon (IMRT/VMAT/SBRT) at Class A centres: USD 4,500–9,500 for full course depending on fractionation and complexity
- Proton therapy at SPHIC or proton centres: USD 35,000–55,000 for full course (vs USD 90,000–140,000 US private)
- Heavy-ion therapy at SPHIC or Wuwei: USD 55,000–85,000 for full course
The Decision Workflow
For most patients, the decision is best made via multidisciplinary tumour-board review. A remote second opinion (see our previous post on the 7-day workflow) typically clarifies whether proton or heavy-ion therapy is genuinely indicated for your case, or whether modern photon SBRT delivers comparable outcomes at meaningful cost saving.
Practical Logistics
A typical proton or heavy-ion course runs 4–8 weeks of daily fractionation. Trip planning should include the full treatment duration plus 1 week pre-treatment workup and 1 week of post-treatment monitoring. Lodging at SPHIC's affiliated guesthouse and similar arrangements at other centres simplifies long-stay logistics.
Sources: SPHIC published outcomes data; particle therapy CCO database; partner-hospital radiation oncology pricing 2026.